Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published Announced on 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The company expects consolidated revenue and profit at each stage to fall below the forecasts due to lower demand for OEM culture media following tighter regulations associated with the implementation of related ordinances in China, lower sales of antigen test kits as infection levels remain low, and lower contract revenue in the cell processing business due to a decline in the number of patients from China.
| Item | Details |
|---|---|
| Net Sales | ¥4,722 million → ¥4,009 million（△15.1％） |
| Operating profit | ¥137 million → ¥-126 million |
| Ordinary income | ¥147 million → ¥-89 million |
| Profit attributable to owners of the parent | ¥110 million → ¥-103 million |
| Net income per share | ¥21.65 → -¥20.22 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | Announced on 15 May 2026 |
| Previous-period results | Consolidated results for the previous fiscal year (fiscal year ended March 2026): consolidated revenue of ¥4,939 million, consolidated operating profit of ¥341 million, consolidated ordinary profit of ¥340 million, net income attributable to owners of the parent of ¥251 million, and consolidated net income per share of ¥49.11 |
| Reason for the revision | The company expects consolidated revenue and profit at each stage to fall below the forecasts due to lower demand for OEM culture media following tighter regulations associated with the implementation of related ordinances in China, lower sales of antigen test kits as infection levels remain low, and lower contract revenue in the cell processing business due to a decline in the number of patients from China. |
| Dividend forecast revision | The year-end dividend was reduced from ¥10 to ¥5 per share. The full-year dividend was also reduced from ¥10 to ¥5 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the tissue culture business, demand for OEM culture media declined as regulations were tightened following the implementation of related ordinances in China. In the microbiology business, sales of antigen test kits are expected to decline because influenza and COVID-19 infections remain at low levels. In the cell processing business, contract revenue is expected to fall below the forecast due to a decline in the number of patients from China. The dividend was reduced in light of the expected loss in order to maintain financial stability and secure retained earnings necessary for business development.